Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CDC25B | P30305 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | APAF1 | O14727 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PTPRC | P08575 | 3/20 | 0.43 |
| ▸ | GALK1 | P51570 | 2/20 | 0.43 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | S100A4 | P26447 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750489 | 0.84 | MEN1 (0.58) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL7921203 | 0.84 | — | — | |
| SCHEMBL9672660 | 0.80 | MEN1 (0.43) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL2996853 | 0.78 | MEN1 (0.43) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL3695046 | 0.73 | CES1 (0.35) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL24062 | 0.72 | MEN1 (0.37) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL9709207 | 0.70 | TDP2 (0.55) | MEN1KMT2ACDC25BPTPRCTDP2 | |
| SCHEMBL9709542 | 0.70 | MAOA (0.62) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL9709023 | 0.70 | MAOA (0.62) | MEN1KMT2ACDC25BMAPTMAOA | |
| SCHEMBL1749823 | 0.70 | GAA (0.50) | MEN1KMT2ACDC25BMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357212-A1 | THIOPHENOXIME AND FURANOXIME SCAFFOLDS | CENTRE NAT RECH SCIENT (FR) | 2023-11-09 | — | — | US | claimed |
| EP-4211129-A1 | THIOPHENOXIME AND FURANOXIME SCAFFOLDS | Centre national de la recherche scientifique (FR) | 2023-07-19 | — | — | EP | claimed |
| WO-2022053628-A1 | THIOPHENOXIME AND FURANOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-03-17 | — | — | WO | claimed |
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | claimed |
| EP-2358673-A1 | NOVEL BIS-AMIDES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-08-24 | — | — | EP | claimed |
| WO-2010058353-A1 | NOVEL BIS-AMIDES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | WO | claimed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | claimed |
| WO-2009109610-A1 | USE OF NAD INFORMATION INHIBITORS FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | TOPOTARGET SWITZERLAND S.A. (CH) | 2009-09-11 | — | — | WO | claimed |
| EP-2073808-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | Topotarget Switzerland SA (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | claimed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | claimed |
| US-5861400-A | TREATING RESISTANCE TO AN ANTHRACYLCINE ANTIBIOTIC WITH ADIKETOPIPERAZINE COMPOUND | XENOVA LIMITED (GB) | 1999-01-19 | — | — | US | claimed |
| WO-1997048397-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048695-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1995021831-A1 | PHARMACEUTICAL PIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-08-17 | — | — | WO | claimed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | claimed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357212-A1 | THIOPHENOXIME AND FURANOXIME SCAFFOLDS | ACHE, PNPO, PSEN2 | MEN1 1185/4885KMT2A 4121/4885CDC25B 1056/4885 |
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | MEN1 2324/4885KMT2A 515/4885CDC25B 516/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | MEN1 3901/4885KMT2A 3424/4885CDC25B 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.